Practical recommendations on treatment of multiple sclerosis with Cladribine: an Israeli Experts Group‏ Viewpoint

被引：3

作者：

Petrou, Panayiota ^{[4
]}

Achiron, Anat ^{[1
]}

Cohen, Esther Ganelin ^{[2
]}

Garty, Maya ^{[3
]}

Magalashvili, David ^{[1
]}

Karmon, Yuval ^{[5
]}

Milo, Ron ^{[6
]}

Regev, Keren ^{[7
]}

Vaknin-Dembinsky, Adi ^{[4
]}

Wilf-Yarkoni, Adi ^{[8
]}

Karussis, Dimitrios ^{[4
]}

机构：

[1] Sheba Med Ctr, Ramat Gan, Israel

[2] Tel Aviv Univ, Schneider Childrens Hosp, Tel Aviv, Israel

[3] Bnei Zion Med Ctr, Haifa, Israel

[4] Hadassah Med Ctr, Jerusalem, Israel

[5] Meir Med Ctr, Kefar Sava, Israel

[6] Barzilai Govt Hosp, Ashqelon, Israel

[7] Tel Aviv Med Ctr & Sch Med, Tel Aviv, Israel

[8] Rabin Med Ctr, Petah Tiqwa, Israel

来源：

JOURNAL OF NEUROLOGY | 2023年 / 270卷 / 11期

关键词：

Multiple sclerosis; Cladribine tablets; Disease activity;

D O I：

10.1007/s00415-023-11846-4

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Cladribine tablets (Mavenclad(& REG;)) were approved by the European Union in 2017 as high-efficacy therapy for highly active relapsing-remitting multiple sclerosis. In Israel, Mavenclad(& REG;) was approved in 2018. Real-life experience has confirmed the efficacy of cladribine tablets over at least 4 years from the initial course. During the last years, several questions were raised concerning the management of people with MS who show disease activity during years 3 and 4 post-cladribine initiation and what treatment decisions are needed beyond year 4. A few expert boards have tried to provide insight based on research data and to suggest recommendations on the therapeutic dilemmas and treatment decisions with cladribine. However, there is currently no widely accepted consensus about these issues. The vast clinical experience gained in Israel in the past 5 years in several MS centers across the country allows for a broad perspective of the outcomes with long-term cladribine use. This article summarizes previously published recent recommendations and describes the insights of Israeli neurology key opinion leaders that convened for an advisory board meeting on January 29th, 2023, with the aim of reaching a consensus regarding cladribine long-term treatment and follow-up.

引用

页码：5188 / 5195

页数：8

共 7 条

[1] Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study [J].